Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Receives Average Recommendation of “Buy” from Analysts

Shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) have been assigned a consensus rating of “Buy” from the nineteen ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $289.37.

Several analysts recently commented on JAZZ shares. Morgan Stanley raised their target price on Jazz Pharmaceuticals from $283.00 to $322.00 and gave the company an “overweight” rating in a research report on Wednesday, August 26th. Piper Sandler increased their price target on Jazz Pharmaceuticals from $301.00 to $310.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 4th. Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a report on Tuesday, June 9th. Wells Fargo & Company lifted their price objective on shares of Jazz Pharmaceuticals from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, TD Cowen upped their price objective on shares of Jazz Pharmaceuticals from $275.00 to $300.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th.

Jazz Pharmaceuticals Trading Up 0.7%

Jazz Pharmaceuticals stock opened at $237.95 on Friday. Jazz Pharmaceuticals has a 52-week low of $125.79 and a 52-week high of $266.38. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $15.45 billion, a price-to-earnings ratio of 16.41, a PEG ratio of 0.21 and a beta of 0.36. The firm has a 50-day moving average price of $248.79 and a two-hundred day moving average price of $227.59.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. Jazz Pharmaceuticals’s revenue for the quarter was up 15.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($8.25) EPS. Sell-side analysts expect that Jazz Pharmaceuticals will post 21.61 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $240.94, for a total value of $289,128.00. Following the completion of the transaction, the executive vice president directly owned 47,671 shares in the company, valued at $11,485,850.74. This trade represents a 2.46% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the transaction, the director owned 360,682 shares in the company, valued at $91,245,332.36. This represents a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 98,121 shares of company stock worth $24,443,842 in the last 90 days. Corporate insiders own 4.10% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sequoia Financial Advisors LLC boosted its stake in Jazz Pharmaceuticals by 9.4% during the second quarter. Sequoia Financial Advisors LLC now owns 4,527 shares of the specialty pharmaceutical company’s stock valued at $1,091,000 after buying an additional 389 shares in the last quarter. Tidal Investments LLC grew its stake in shares of Jazz Pharmaceuticals by 8.3% in the 2nd quarter. Tidal Investments LLC now owns 21,028 shares of the specialty pharmaceutical company’s stock worth $5,067,000 after purchasing an additional 1,615 shares during the last quarter. WINTON GROUP Ltd bought a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $386,000. Integrated Wealth Concepts LLC raised its holdings in shares of Jazz Pharmaceuticals by 27.2% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 1,762 shares of the specialty pharmaceutical company’s stock worth $425,000 after purchasing an additional 377 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in Jazz Pharmaceuticals by 15.7% during the second quarter. NewEdge Advisors LLC now owns 2,285 shares of the specialty pharmaceutical company’s stock valued at $551,000 after purchasing an additional 310 shares during the last quarter. 89.14% of the stock is owned by institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.